Recruiting

tDCS

Sponsor:

University of Michigan Rogel Cancer Center

Code:

NCT07673614

Conditions

Chemotherapy-Induced Peripheral Neuropathy

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Sham Intervention

Survey Administration

Transcranial Direct Current Stimulation

Study Details

Brief summary:

This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.

Conditions

Chemotherapy-Induced Peripheral Neuropathy

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Study ID

NCT07673614

Start date

Sep 10, 2026

Status verified date

Oct, 2026

Completion date

Feb, 2028

Anticipated

Primary completion date

Feb, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 18 to 85 years of age
  • Diagnosis of cancer, stages I-IV
  • Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy)
  • Presence of CIPN defined as new, length-dependent numbness, tingling, and/or pain that developed with neurotoxic chemotherapy
  • CIPN20 score ≥ 20
  • Able to walk unassisted
  • Proficient in English

Exclusion Criteria:

  • Known brain metastases
  • Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN)
  • History of brain or spinal surgery
  • Neuropathy other than CIPN
  • Significant hearing or vision deficits
  • Vestibulopathy
  • Currently receiving chemotherapy, radiation therapy, or immunotherapy
  • Contraindications to transcranial direct current stimulation (tDCS), including recent seizures
  • Presence of metallic objects in the head
  • Presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices)
  • Active scalp dermatological conditions

Study Design

Enrollment

50 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Arm I (active tDCS)

Patients undergo tDCS to the sensorimotor cortex, using the Starstim-8™ system, for 20 minutes. One week later, patients cross-over to Arm II.

sham comparator: Arm II (sham tDCS)

Patients undergo sham tDCS to the sensorimotor cortex, using the Starstim-8™ system, for 20 minutes. One week later, patients cross-over to Arm I.

Interventions

Sham Intervention

Undergo sham tDCS

Survey Administration

Ancillary studies

Transcranial Direct Current Stimulation

Undergo tDCS

Primary outcome measure

  • Vibration detection threshold [ Time Frame: at weeks 2 and 3 ]

Central Contacts and Locations

Central contacts

Eshaka Eshwar

734-232-5901eshaka@med.umich.edu

Locations

University of Michigan Rogel Cancer Center

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Eshaka Eshwar

734-232-5901eshaka@med.umich.edu

Principal Investigator:

Brendan L. McNeish

More Information

Sponsor

University of Michigan Rogel Cancer Center

Last update posted

Oct 6, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-07. This information was provided to ClinicalTrials.gov by University of Michigan Rogel Cancer Center on 2026-10-06. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.